Teva acquires BioXcel’s BXCL501, under FDA review for at-home agitation use; Rumi Therapeutics gains an option on Enthorin’s Fragile X PDE2 inhibitor.
Publication|Videos|July 31, 2023
Deep Dive into the Use of Real-World Registry Data as External Control Arms
Author(s)CorEvitas
While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.
Advertisement
Watch this video and learn more:
- Challenges faced by biopharma companies conducting clinical trials when studying rare conditions.
- The purpose of a control population in traditional randomized controlled clinical trials.
- How hybrid control arms can improve the strength of control groups.
- How prospective registries serve as real-world control populations.
- How to minimize bias between populations or outcome measures across RCT control groups vs. real-world/hybrid controls.
Advertisement
Related to this article
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Shionogi’s Dr. Draica on how XOCOVA blocks viral replication between exposure and symptoms — and why it works even with prior immunity.
Phagenyx’s Chad Hoskins on why AHA/ASA guideline inclusion gives stroke teams a basis to use PES earlier — and what the evidence shows.
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron Lanton Report on how value is defined across healthcare.
Pfizer’s talazoparib-enzalutamide combination moves to earlier line in prostate cancer, with eligibility tied to genetic testing and immature survival data.
Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
FDA Extends Talzenna-Xtandi to Hormone-Sensitive Prostate Cancer
3
Pathos Ai Enters Drug Development Collaboration with Bristol Myers Squibb and Tempus Ai
4
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
5